STAFFORD, Texas, April 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused…
On track to announce primary endpoint result from ORIGIN 3 trial this quarter (2Q 2025)U.S. FDA BLA submission for accelerated…
-- Novel, locally administered gene therapy designed to boost cellular production of anti-inflammatory protein IL-1Ra in the knee -- --…
MELBOURNE, Australia and SAN FRANCISCO, April 03, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the…
CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on…
MNV-201 is Minovia’s second generation mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria Rare…
Press release LIfT BioSciences gains access to half a million allogeneic donors through collaboration with Gift of Life Biologics Access…
Agreement with Hercules Capital significantly increases financial and operational strength, provides up to $500 million in capital with no dilution…
SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology…
Press release LIfT BioSciences gains access to half a million allogeneic donors through collaboration with Gift of Life Biologics Access…